TDMS Study 05197-12 Pathology Tables
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:14
FINAL#1, REVISION #1
Facility: Battelle Northwest
Chemical CAS #: 111-76-0002
Lock Date: 11/08/96
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:14
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 62.5 PPM 125 PPM 250 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Natural Death 6 3 5 4
Moribund Sacrifice 14 16 12 10
Accidently Killed 1
Survivors
Terminal Sacrifice 29 31 33 36
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (43) (43) (46) (46)
Intestine Small, Duodenum (45) (49) (47) (47)
Polyp Adenomatous 1 (2%)
Intestine Small, Jejunum (46) (49) (47) (48)
Carcinoma 1 (2%)
Intestine Small, Ileum (46) (50) (47) (48)
Carcinoma 1 (2%)
Liver (50) (50) (49) (50)
Hemangiosarcoma 1 (2%)
Hepatocellular Carcinoma 7 (14%) 10 (20%) 11 (22%) 9 (18%)
Hepatocellular Carcinoma, Multiple 3 (6%) 2 (4%) 2 (4%) 1 (2%)
Hepatocellular Adenoma 9 (18%) 5 (10%) 5 (10%) 8 (16%)
Hepatocellular Adenoma, Multiple 7 (14%) 3 (6%) 2 (4%)
Hepatocholangiocarcinoma 2 (4%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Mesentery (10) (4) (5) (9)
Hemangioma 1 (10%)
Hemangiosarcoma 1 (25%)
Osteosarcoma 1 (20%)
Sarcoma, Metastatic, Skin 2 (20%)
Pancreas (49) (50) (49) (50)
Salivary Glands (48) (50) (49) (50)
Parotid Gland, Hemangioma 1 (2%)
Stomach, Forestomach (50) (50) (49) (50)
Hemangioma 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%) 2 (4%) 5 (10%)
Stomach, Glandular (48) (50) (49) (49)
Tongue (1) (1)
Squamous Cell Carcinoma 1 (100%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:14
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 62.5 PPM 125 PPM 250 PPM
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Adrenal Medulla (50) (50) (49) (50)
Pheochromocytoma Benign 3 (6%) 1 (2%) 1 (2%)
Bilateral, Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (50) (50) (49) (50)
Adenoma 2 (4%) 1 (2%)
Pituitary Gland (50) (49) (48) (49)
Pars Distalis, Adenoma 5 (10%) 8 (16%) 8 (17%) 4 (8%)
Pars Distalis, Carcinoma 1 (2%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (50) (50) (50) (49)
Follicular Cell, Adenoma 1 (2%) 2 (4%) 5 (10%) 1 (2%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (50) (49) (49) (49)
Cystadenoma 2 (4%) 1 (2%) 3 (6%)
Granulosa Cell Tumor Benign 1 (2%)
Hemangioma 1 (2%)
Teratoma Benign 2 (4%)
Teratoma Malignant 1 (2%)
Uterus (50) (50) (49) (50)
Adenoma 1 (2%)
Hemangiosarcoma 2 (4%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Polyp Stromal 1 (2%) 2 (4%) 4 (8%) 2 (4%)
Sarcoma Stromal 1 (2%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:14
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 62.5 PPM 125 PPM 250 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%)
Lymph Node (4) (7) (6) (1)
Sarcoma, Metastatic, Skin 1 (25%)
Renal, Sarcoma, Metastatic, Skin 1 (25%)
Renal, Teratoma Malignant, Metastatic, Ovary 1 (17%)
Lymph Node, Bronchial (41) (39) (41) (37)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%)
Lymph Node, Mandibular (37) (38) (40) (38)
Histiocytic Sarcoma 1 (3%)
Lymph Node, Mesenteric (47) (48) (49) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%)
Lymph Node, Mediastinal (31) (40) (38) (34)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%)
Spleen (50) (50) (49) (50)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Thymus (46) (41) (46) (48)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (50) (50) (50) (50)
Carcinoma 1 (2%) 3 (6%)
Skin (50) (50) (50) (50)
Sebaceous Gland, Adenoma 1 (2%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Sarcoma 2 (4%) 1 (2%)
Subcutaneous Tissue, Sarcoma, Multiple 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
Osteosarcoma 1 (2%)
Skeletal Muscle (1)
Hemangiosarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:14
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 62.5 PPM 125 PPM 250 PPM
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 5 (10%) 2 (4%) 4 (8%) 1 (2%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (4%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 4 (8%) 3 (6%) 6 (12%) 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Sarcoma, Metastatic, Skin 1 (2%) 1 (2%)
Mediastinum, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (2%)
Mediastinum, Osteosarcoma, Metastatic, Bone 1 (2%)
Mediastinum, Sarcoma, Metastatic, Skin 1 (2%)
Nose (50) (50) (49) (50)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (6) (4) (3) (4)
Adenoma 4 (67%) 3 (75%) 2 (67%) 3 (75%)
Carcinoma 1 (17%) 1 (25%) 1 (33%) 2 (50%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (49) (50)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Urinary Bladder (47) (49) (48) (50)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 1 (2%) 2 (4%)
Lymphoma Malignant 7 (14%) 9 (18%) 10 (20%) 7 (14%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:14
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 62.5 PPM 125 PPM 250 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 43 38 38 35
Total Primary Neoplasms 76 63 76 52
Total Animals with Benign Neoplasms 31 23 27 18
Total Benign Neoplasms 44 30 42 27
Total Animals with Malignant Neoplasms 27 26 28 22
Total Malignant Neoplasms 32 33 34 25
Total Animals with Metastatic Neoplasms 9 4 7 3
Total Metastatic Neoplasm 18 4 7 8
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:14
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 62.5 PPM 125 PPM 250 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 7 8 13 10
Natural Death 4 3 10 14
Survivors
Terminal Sacrifice 39 39 27 26
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (48) (48) (44) (43)
Intestine Small, Jejunum (48) (47) (43) (38)
Histiocytic Sarcoma 1 (3%)
Intestine Small, Ileum (48) (47) (43) (39)
Carcinoma 1 (2%)
Liver (50) (50) (49) (49)
Carcinoma, Metastatic, Islets, Pancreatic 1 (2%)
Hemangiosarcoma 1 (2%) 2 (4%) 4 (8%)
Hepatocellular Carcinoma 5 (10%) 8 (16%) 12 (24%) 16 (33%)
Hepatocellular Carcinoma, Multiple 5 (10%) 3 (6%) 4 (8%) 5 (10%)
Hepatocellular Adenoma 13 (26%) 10 (20%) 13 (27%) 14 (29%)
Hepatocellular Adenoma, Multiple 9 (18%) 8 (16%) 5 (10%) 3 (6%)
Hepatocholangiocarcinoma 1 (2%)
Histiocytic Sarcoma 2 (4%)
Mesentery (5) (3) (3) (1)
Histiocytic Sarcoma 1 (100%)
Oral Mucosa (1)
Squamous Cell Carcinoma 1 (100%)
Pancreas (50) (50) (47) (47)
Hemangioma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Salivary Glands (50) (50) (48) (50)
Stomach, Forestomach (50) (50) (49) (48)
Histiocytic Sarcoma 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%) 1 (2%) 2 (4%) 2 (4%)
Stomach, Glandular (50) (50) (46) (47)
Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:14
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 62.5 PPM 125 PPM 250 PPM
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (49) (50)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Capsule, Adenoma 2 (4%) 2 (4%) 2 (4%)
Adrenal Medulla (49) (50) (49) (49)
Pheochromocytoma Malignant 1 (2%)
Islets, Pancreatic (50) (50) (47) (46)
Adenoma 2 (4%)
Carcinoma 1 (2%)
Thyroid Gland (50) (48) (49) (50)
Follicular Cell, Adenoma 2 (4%) 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (49) (50)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Leiomyoma 1 (2%)
Prostate (49) (49) (48) (45)
Seminal Vesicle (50) (49) (46) (46)
Histiocytic Sarcoma 1 (2%)
Testes (50) (50) (49) (50)
Interstitial Cell, Adenoma 2 (4%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (49) (50)
Hemangiosarcoma 1 (2%) 2 (4%)
Histiocytic Sarcoma 1 (2%)
Lymph Node (2) (1) (1)
Schwannoma Malignant, Metastatic, Spinal Cord 1 (50%)
Lymph Node, Bronchial (38) (35) (33) (35)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%)
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:14
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 62.5 PPM 125 PPM 250 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Lymph Node, Mandibular (24) (26) (32) (25)
Lymph Node, Mesenteric (50) (50) (47) (43)
Histiocytic Sarcoma 1 (2%)
Lymph Node, Mediastinal (40) (33) (40) (37)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%)
Histiocytic Sarcoma 1 (3%)
Spleen (50) (50) (48) (49)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mast Cell Tumor NOS 1 (2%)
Thymus (43) (43) (36) (37)
Histiocytic Sarcoma 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (49) (50)
Hemangioma 1 (2%)
Prepuce, Histiocytic Sarcoma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Hemangiosarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (49) (50)
Spinal Cord (2)
Schwannoma Malignant 1 (50%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (50) (50) (48) (49)
Lung (50) (50) (49) (50)
Alveolar/Bronchiolar Adenoma 7 (14%) 7 (14%) 8 (16%) 8 (16%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (4%) 2 (4%)
Alveolar/Bronchiolar Carcinoma 5 (10%) 2 (4%) 2 (4%) 3 (6%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 7 (14%) 5 (10%) 5 (10%) 3 (6%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Mediastinum, Hepatocholangiocarcinoma,
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:14
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 62.5 PPM 125 PPM 250 PPM
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Metastatic, Liver 1 (2%)
Nose (50) (50) (48) (48)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (3) (3) (2) (2)
Adenoma 3 (100%) 3 (100%) 2 (100%) 2 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (47) (50)
Histiocytic Sarcoma 1 (2%)
Urinary Bladder (50) (50) (46) (45)
Histiocytic Sarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Lymphoma Malignant 1 (2%) 3 (6%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 05197-12 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC 2-BUTOXYETHANOL Date: 08/23/99
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 11:23:14
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 62.5 PPM 125 PPM 250 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 42 33 36 41
Total Primary Neoplasms 62 55 60 69
Total Animals with Benign Neoplasms 30 28 26 28
Total Benign Neoplasms 42 32 37 33
Total Animals with Malignant Neoplasms 19 16 19 28
Total Malignant Neoplasms 20 22 23 36
Total Animals with Metastatic Neoplasms 9 5 5 4
Total Metastatic Neoplasm 12 6 5 4
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant 1
Total Uncertain Neoplasms 1
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------